JP2008533161A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008533161A5 JP2008533161A5 JP2008501998A JP2008501998A JP2008533161A5 JP 2008533161 A5 JP2008533161 A5 JP 2008533161A5 JP 2008501998 A JP2008501998 A JP 2008501998A JP 2008501998 A JP2008501998 A JP 2008501998A JP 2008533161 A5 JP2008533161 A5 JP 2008533161A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- use according
- composition
- antagonist
- pparγ
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 239000002246 antineoplastic agent Substances 0.000 claims 10
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 7
- 206010038389 Renal cancer Diseases 0.000 claims 7
- 201000010982 kidney cancer Diseases 0.000 claims 7
- 239000002955 immunomodulating agent Substances 0.000 claims 6
- 229940121354 immunomodulator Drugs 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 102000000536 PPAR gamma Human genes 0.000 claims 4
- 108010016731 PPAR gamma Proteins 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 239000003873 peroxisome proliferator activated receptor gamma antagonist Substances 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 3
- 206010057644 Testis cancer Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 3
- 230000002584 immunomodulator Effects 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical class O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- 108010006654 Bleomycin Proteins 0.000 claims 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 102000008072 Lymphokines Human genes 0.000 claims 2
- 108010074338 Lymphokines Proteins 0.000 claims 2
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 2
- 229940121742 Serine/threonine kinase inhibitor Drugs 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 229960001561 bleomycin Drugs 0.000 claims 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 2
- 229960005243 carmustine Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 229960005420 etoposide Drugs 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 239000003667 hormone antagonist Substances 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 2
- 229940047124 interferons Drugs 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 2
- 229960000624 procarbazine Drugs 0.000 claims 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 2
- 239000003207 proteasome inhibitor Substances 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- KNOYHJOPRUTPSQ-QHCPKHFHSA-N (4s)-5-amino-5-oxo-4-[3-[4-(4-phenylphenyl)phenyl]propanoylamino]pentanoic acid Chemical compound C1=CC(CCC(=O)N[C@@H](CCC(O)=O)C(=O)N)=CC=C1C1=CC=C(C=2C=CC=CC=2)C=C1 KNOYHJOPRUTPSQ-QHCPKHFHSA-N 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66102405P | 2005-03-14 | 2005-03-14 | |
| PCT/US2006/009309 WO2006099479A2 (en) | 2005-03-14 | 2006-03-14 | Methods of treating cancer using ppar-gamma antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008533161A JP2008533161A (ja) | 2008-08-21 |
| JP2008533161A5 true JP2008533161A5 (https=) | 2009-05-07 |
Family
ID=36992402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008501998A Pending JP2008533161A (ja) | 2005-03-14 | 2006-03-14 | ＰＰＡＲ−γアンタゴニストを使用するがんの治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060217425A1 (https=) |
| EP (1) | EP1858512A4 (https=) |
| JP (1) | JP2008533161A (https=) |
| AU (1) | AU2006223000B2 (https=) |
| CA (1) | CA2600712A1 (https=) |
| WO (1) | WO2006099479A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008094860A2 (en) | 2007-01-30 | 2008-08-07 | Allergan, Inc. | Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists |
| US20080206194A1 (en) * | 2007-02-16 | 2008-08-28 | Glazer Robert I | Method for the treatment of breast cancer |
| CA2761120A1 (en) * | 2009-05-06 | 2010-11-11 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| EP4490147A1 (en) * | 2022-03-08 | 2025-01-15 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
| CA3254026A1 (en) * | 2022-03-08 | 2023-09-14 | Flare Therapeutics Inc. | Inverse PPARG agonists and their uses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7585512B1 (en) * | 1990-05-08 | 2009-09-08 | Thomas Jefferson University | Composition and method of using tumor cells |
| ATE462433T1 (de) * | 1996-12-11 | 2010-04-15 | Dana Farber Cancer Inst Inc | Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums |
| WO2001083427A1 (en) * | 2000-04-28 | 2001-11-08 | Sankyo Company, Limited | PPARη MODULATORS |
| WO2002076177A2 (en) * | 2001-03-23 | 2002-10-03 | Bethesda Pharmaceuticals, Inc. | Design and synthesis of optimized ligands for ppar |
| US6972175B2 (en) * | 2002-11-27 | 2005-12-06 | David Pinsky | Inhibition of Egr-1 expression by ppar-gamma agonists and related compositions and methods |
| KR100576575B1 (ko) * | 2003-09-16 | 2006-05-04 | 한국생명공학연구원 | 피피에이알감마에 대한 단일클론 항체, 특이 항체분비 융합세포주 및 항체를 이용한 염증, 암, 대사성 질환과 같은 질병 관련 조절인자를 검색하는 방법 |
| WO2005077126A2 (en) * | 2004-02-10 | 2005-08-25 | Boston Medical Center Corporation | Use of ppargamma specific inhibitors as anti-cancer therapeutics |
-
2006
- 2006-03-14 AU AU2006223000A patent/AU2006223000B2/en not_active Ceased
- 2006-03-14 US US11/376,598 patent/US20060217425A1/en not_active Abandoned
- 2006-03-14 WO PCT/US2006/009309 patent/WO2006099479A2/en not_active Ceased
- 2006-03-14 CA CA002600712A patent/CA2600712A1/en not_active Abandoned
- 2006-03-14 JP JP2008501998A patent/JP2008533161A/ja active Pending
- 2006-03-14 EP EP06738374A patent/EP1858512A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2809657T1 (en) | New therapeutic agents | |
| RU2468021C2 (ru) | Гетероциклические соединения и их применение | |
| JP2009514881A5 (https=) | ||
| JP2022508155A5 (https=) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2017528524A5 (https=) | ||
| RU2008122046A (ru) | Аминопиримидины в качестве ингибиторов киназ | |
| FI3694529T3 (fi) | Trispesifiset proteiinit ja niiden käyttömenetelmät | |
| JP2016538344A5 (https=) | ||
| JP2016504365A5 (https=) | ||
| JP2013522292A5 (https=) | ||
| JP2010540556A5 (https=) | ||
| JP2018530554A5 (https=) | ||
| JP2013544799A5 (https=) | ||
| JP2017521420A5 (https=) | ||
| JP2008535902A5 (https=) | ||
| JP2015512943A5 (https=) | ||
| JP2019529518A5 (https=) | ||
| JP2015520770A5 (https=) | ||
| JP2019534865A5 (https=) | ||
| JP2016512831A5 (https=) | ||
| JP2017526662A5 (https=) | ||
| JP2012509265A5 (https=) | ||
| JP2013523680A5 (https=) | ||
| JP2017524013A5 (https=) |